Melfor - instructions for use, dose, side effects, contraindications

Description:Hard gelatin capsules number 0. The body and the lid are white, opaque. The contents of the capsules are white or almost white crystalline powder with varying degrees of particle refinement, with a slight odor. Hygroscopic. Densification of the contents of the capsule according to the shape of the capsule is allowed.

Pharmacotherapeutic group:Metabolic means

ATX: & nbsp

C.01.E.B.22 Meldoney

C.01.E.B Other drugs for the treatment of heart disease

Pharmacodynamics:

Synthetic analogue of gamma-butyrobetaine, suppresses gamma-butyrobetaine hydroxynase, reduces synthesis of carnitine and transport of long chain fatty acids through cell membranes, prevents the accumulation of activated forms of unoxidized fatty acids - acylcarnitine and acylcoenzyme derivatives - in the cells.As a result of a decrease in the concentration of carnitine, gamma-butyrobetaine, which has vasodilating properties, is synthesized intensively. Under conditions of ischemia, it restores the equilibrium of the processes of oxygen delivery and its consumption in cells, prevents the violation of ATP transport; simultaneously, it activates glycolysis, which proceeds without additional consumption of oxygen. The mechanism of action determines the variety of its pharmacological effects: increasing efficiency, reducing the symptoms of mental and physical overstrain, the activation of tissue and humoral immunity, cardioprotective action. In the case of acute ischemic damage, the myocardium slows the formation of the necrotic zone, shortens the rehabilitation period. With heart failure increases myocardial contractility, increases exercise tolerance, reduces the incidence of angina attacks. In acute and chronic ischemic disorders of cerebral circulation improves blood circulation in the ischemic focus, promotes redistribution of blood in favor of the ischemic site. Characteristic is also a tonic effect on the central nervous system, elimination of functional disorders of somatic and autonomic nervous systems in patients with chronic alcoholism during the period of abstinence.

Pharmacokinetics:

After ingestion, the drug is rapidly absorbed, bioavailability is 78%. The maximum concentration in the blood plasma is achieved 1-2 hours after ingestion. Metabolized in the body with the formation of two major metabolites, which are excreted by the kidneys. The half-life at ingestion depends on the dose, is 3-6 hours.

Indications:

Reduced performance, increased physical activity, postoperative period to accelerate rehabilitation.

As a part of combined therapy of coronary heart disease (exertional angina, myocardial infarction), chronic heart failure, cardialgia against dyshormonal myocardial dystrophy.

Complex therapy of abstinence alcohol syndrome.

In complex therapy of acute and chronic forms of cerebral circulation disorders.

Contraindications:

Hypersensitivity, increased intracranial pressure (with violation of venous outflow and intracranial tumors), pregnancy, lactation, children under 18 years.

Carefully:Chronic liver and kidney disease.

Dosing and Administration:

Inside, before meals, in view of the exciting effect, it is advisable to apply in the morning.

Elevated physical activity 250 mg 4 times a day. The course of treatment is 10-14 days. If necessary, the treatment is repeated after 2-3 weeks. Athletes are prescribed 500-1000 mg 2 times a day before training. The duration of the course in the preparatory period is 14-21 days, during the competition period - 10-14 days.

With cardiovascular diseases (as part of complex therapy):

Stable exertional angina - 250 mg 3 times a day for 3-4 days, then 250 mg 3 times a day 2 times a week for 1-1.5 months.

Myocardial infarction: in the acute period - intravenously, then inside by 500 mg per day, applying the entire dose at once or 2 times a day.

Chronic heart failure - 500-1000 mg once a day. The course of treatment is 4-6 weeks.

Cardialgia against the background of dyshormonal myocardial dystrophy 250 mg twice a day. The course of treatment is 12 days.

Violation of cerebral circulation: in an acute period intravenously, then 500 mg per day, preferably in the first half of the day. The course of treatment is 4-6 weeks.

An abstinent alcoholic syndrome (as part of a combination of specific therapy) 500 mg 4 times a day. The course of treatment is 7-10 days.

Side effects:

Rarely - allergic reactions, dyspepsia, tachycardia, agitation, lowering blood pressure.

Overdose:Treatment is symptomatic.

Interaction:

Strengthens the coronarodilating and some hypotensive drugs, cardiac glycosides. You can combine with antianginal drugs, anticoagulants, antiaggregants, antiarrhythmic drugs, diuretics, bronchodilators. In view of the possible development of moderate tachycardia and reduction in blood pressure, caution should be exercised when combined with nitroglycerin, nifedipine, alpha-adrenoblockers, antihypertensive drugs and peripheral vasodilators.

Special instructions:

It can give a false positive result in the conduct of doping control.

Form release / dosage:

Capsules 250 mg.

Packaging:

For 5, 10, 30 capsules are placed in a contour cell package from the film polyvinylchloride and aluminum foil printed lacquered. 10, 20, 30, 40, 50 or 100 capsules are placed in a polymer container for medicines. One container or 1, 2, 3, 4, 6 or 10 contour mesh packages together with the instruction for use are placed in a pack of cardboard.

Storage conditions:

Store in a dry, dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after expiry date.

Terms of leave from pharmacies:On prescription

Registration number:LSR-009044/10

Date of registration:31.08.2010 / 18.10.2017

Expiration Date:Unlimited

Manufacturer: & nbsp

BIOCHEMIST, OJSC Russia

Information update date: & nbsp23.04.2018

Illustrated instructions

Instructions

Melfor® (Melfor)